Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDNA 223

Drug Profile

MDNA 223

Alternative Names: Anti-PD1-IL-2BiSKIT; Anti-PD1-MDNA-109-FEAA; MDNA-109-FEAA; MDNA-223

Latest Information Update: 09 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicenna Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 03 Oct 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Medicenna Therapeutics
  • 01 Aug 2023 Medicenna Therapeutics has patent protection for Interleukin-2 Fusion Proteins and Uses Thereof in USA
  • 05 Jan 2023 Medicenna Therapeutics has patent protection for methods of treating cancer with an IL-2 superkine such as MDNA 11 and a PD1, PDL1 or CTLA-4 checkpoint inhibitor in combination, or as a single agent using BiSKIT™ platform in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top